Marchés français ouverture 2 h 5 min

Quantum Genomics Société Anonyme (ALQGC.PA)

Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
3,8800+0,4550 (+13,28 %)
À la clôture : 5:36PM CET
Plein écran
Clôture précédente3,4250
Ouverture3,4900
Offre0,0000 x 0
Vente0,0000 x 0
Var. jour3,4650 - 3,9000
Sur 52 semaines1,5100 - 4,4800
Volume984 276
Volume moyen312 164
Cap. boursière81,104M
Bêta (mensuel sur 5 ans)0,73
Rapport P/E (sur 12 mois)S.O.
BPA (sur 12 mois)-0,4940
Date de bénéficesS.O.
Dividende et rendement à termeS.O. (S.O.)
Date ex-dividendeS.O.
Objectif sur 1 an9,86
  • Globe Newswire

    Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals

    Quantum Genomics to receive up to $11.35 million in upfront and milestone payments plus double-digit royalties on sales Xediton Pharmaceuticals to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Canada PARIS and NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Xediton Pharmaceuticals to develop and commercialize firibastat in Canada. Under the terms of the agreement, Xediton Pharmaceuticals will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Canada. Quantum Genomics has already recruited patients in Canada for the pivotal phase III study FRESH. Quantum Genomics will receive upfront and milestone payments amounting up to $11.35 million, plus double-digit royalties on sales. The population suffering from difficult to treat and resistant hypertension in the above territories is estimated to be between 1 and 1.5 million. “We are proud to partner firibastat with Xediton Pharmaceuticals, a private-held specialty Pharma. We share common values: positively impact the lives of our patients through our products and physicians. With an experienced management team, Xediton Pharmaceuticals is a fully operational company having already three assets in cardiovascular on the market,” mentioned Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics. “We are very pleased to partner with Quantum Genomics to bring to Canadian patients Firibastat. While there are numerous treatments in hypertension, there is not much available for patients who are resistant to current treatments. We are looking forward to Firibastat being on the market, as it will be of tremendous benefit to patients with difficult to treat/resistant hypertension and heart failure,” said George Gafrey, President of XEDITON Pharmaceuticals Inc. About Xediton Pharmaceuticals Xediton Pharmaceuticals is a privately-held pharmaceutical company with a focus on meeting the needs of patients, physicians and partners. Xediton Pharmaceuticals is committed to developing, partnering and making available new and established medicines to promote the health of Canadians. Located in the Greater Toronto Area, Canada, Xediton Pharmaceuticals has products in Oncology, Anti-Infectives, Pain, GI, Ophthalmology and CV and has built strong strategic alliances with Global and International Healthcare and pharmaceutical companies. For more information, please visit www.xediton.com. About Quantum Genomics Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years). Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF). For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn. Contact information Quantum Genomics Jean-Philippe MilonCEOjean-philippe.milon@quantum-genomics.comBenoît GueugnonCFO benoit.gueugnon@quantum-genomics.comSo Bang (Europe)  Nathalie BoumendilFinancial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel BeaupainMedia Relations and Scientific Communications+33 (0)6 88 48 48 02 | samuel@so-bang.frLifeSci (USA) Dan FerryFinancial Communications +1 (617) 430-7576 | Daniel@lifesciadvisors.com Mike TattoryMedia Relations and Scientific Communications+1 (609) 802-6265 | mtattory@lifescicomms.com

  • Globe Newswire

    Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical

    Quantum Genomics to receive up to $50 million in upfront and milestone payments plus double-digit royalties on sales Qilu Pharmaceutical to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in Greater China region, including Hong Kong and Macao PARIS and NEW YORK, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical to develop and commercialize firibastat in Greater China region, Hong Kong and Macao. After its first partnership in Asia, this new agreement is the second step of Quantum Genomics’ partnering strategy in Asia. Under the terms of the agreement, Qilu Pharmaceutical will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Geater China region including Hong Kong and Macao. Additionally, Qilu Pharmaceutical plans to join the global  study of difficult to treat/resistant hypertension in China. Quantum Genomics will receive upfront and milestone payments amounting up to $50 million, plus double-digit royalties on sales. The population suffering from difficult to treat and resistant hypertension in the above territories is estimated to be between 25 and 30 million. “Qilu Pharmaceutical is one of the leading pharmaceutical companies in China with 5 R&D centers across US and China and 10 domestic manufacturing sites. Qilu Pharmaceutical has launched over 200 products in China, is a leading player in the cardiovascular field and has established long-term cooperative relationships with international companies. With a comprehensive sales network and multiple professional in marketing, Qilu Pharmaceutical is a partner of choice and we look forward to working with them,” mentioned Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics. “Quantum Genomics is the leading biopharmaceutical company specializing in the development of a new drug class based on the central action mechanism of Aminopeptidase A inhibition” said Dr. Binhui (Ben) Ni, Chief Business & Investment Officer, corporate vice president of Qilu Pharmaceutical,  “Development of Firibastat, first-in-class for the treatment of high blood pressure and/or in combination with others anti-hypertensive drugs offers alternative treatments to address the significant unmet needs in China.  We are confident that the unique mechanism of action with strong clinical data position Firibastat to make a meaningful impact on patients’ lives.” About Qilu Pharmaceutical Qilu Pharmaceutical is one of the leading pharmaceutical companies in China, with mission of caring through Science and Technology. The company develops, manufactures and commercializes novel pharmaceuticals, biologics, as well as generics and biosimilars. Qilu has 12 subsidiaries, and 10 manufacturing sites with over 23000 employees worldwide and launched over 200 products in China with revenue of over 3.3 bn USD in 2019. Qilu Pharmaceutical is among the top GMP manufacturers in the world, fully complied with major global regulatory agencies and exports the products including active pharmaceutical ingredients (APIs) & finished formulations over 70 countries. With commitment to develop innovative medicines for solutions that improve people's lives and meet the unmet medical need in multiple therapeutic areas, Qilu has 2000+ dedicated scientists and comprehensive clinical team that work in its R&D centers across US and China. The company is actively looking for partnership with global players via in-/out-licensing and/or co-development strategy. About Quantum Genomics Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years). Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF). For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedIn. Contact information Quantum Genomics Jean-Philippe MilonCEOjean-philippe.milon@quantum-genomics.comBenoît GueugnonCFO benoit.gueugnon@quantum-genomics.comSo Bang (Europe)  Nathalie BoumendilFinancial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel BeaupainMedia Relations and Scientific Communications+33 (0)6 88 48 48 02 | samuel@so-bang.frLifeSci (USA) Dan FerryFinancial Communications +1 (617) 430-7576 | Daniel@lifesciadvisors.com Mike TattoryMedia Relations and Scientific Communications+1 (609) 802-6265 | mtattory@lifescicomms.com

  • Globe Newswire

    Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)

    Quantum Genomics to receive up to $19 million in upfront and milestone payments plus double-digit royalties on sales OEP to receive an exclusive license to develop and commercialize firibastat for the treatment of difficult to treat/resistant hypertension in South-East Asia, Australia and New ZealandPARIS and NEW YORK, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension today announced it has entered into an exclusive licensing and collaboration agreement with Orient EuroPharma (OEP) to develop and commercialize firibastat in South East Asia, Australia and New-Zealand. After its first partnership in Latin America, this new agreement is the first step of Quantum Genomics’ partnering strategy in Asia.Under the terms of the agreement, OEP will receive exclusive commercialization rights to firibastat for the treatment of difficult to treat/resistant hypertension in Taiwan, Malaysia, the Philippines, Singapore, Vietnam, Thailand, Indonesia, Myanmar, Cambodia, Australia and New-Zealand. Additionally, OEP will fund part of the Phase III study in difficult to treat/resistant hypertension in Taiwan as part of the overall pivotal Phase III trial led by Quantum Genomics.Quantum Genomics will receive upfront and milestone payments amounting up to $19 million, plus double-digit royalties on sales.The population suffering from difficult to treat and resistant hypertension in the above territories is estimated to be 10 million.“OEP is the ideal partner for us with its experienced commercialization team, including dedicated sales forces, marketers, and existing successful partnerships with well-known companies in Asia, Europe and America. OEP has launched and marketed multiple cardiovascular drugs, and their proven track record and experience will be invaluable for the success of firibastat. This partnership highlights OEP’s long-term confidence in firibastat and we look forward to working with them,” mentioned Jean-Philippe Milon, CEO of Quantum Genomics.Calvin Tsai, CEO of Orient EuroPharma, said: “OEP is always committed to improving human health, constantly seeking and launching innovative products to meet patients’ need. The Phase IIb results of firibastat in arterial hypertension are promising. Firibastat's profile on difficult-to-treat and treatment-resistant hypertension fits well into our current cardiovascular product portfolio and Asian expansion strategy. We are excited to have the opportunity to bring this potentially transformative drug to Taiwan, South-East Asia, Australia and New Zealand. We are looking forward to a successful cooperation with Quantum Genomics.”About Orient EuroPharma Founded in 1982, Orient EuroPharma (OEP) became officially listed in the Taiwan Exchange in 2003. In the beginning, the Company was a prescription drug distributor, but has now become a full-scale, multinational pharmaceutical company. The core competencies of the Company not only include pharmaceutical innovation, R&D, manufacturing, sales and clinical trials, but has significantly increased the Company's operational efficiency through vertical integration to provide customers with more complete services. In 2019, the Company exceeded 1,000 employees worldwide, of which about 40% are overseas personnel, and the combined turnover exceeded NT$6 billion.About Quantum Genomics Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Collège de France (French National Institute of Health and Medical Research (INSERM)/ the Scientific Centre for National Research (CNRS)). The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with severe heart failure dies within five years).Based in Paris and New York, Quantum Genomics is listed on the Euronext Growth exchange in Paris (FR0011648971- ALQGC) and trades on the OTCQX Best Market in the United States (symbol: QNNTF).For more information, please visit www.quantum-genomics.com, or follow us on Twitter and LinkedInContact information Quantum Genomics  Jean-Philippe Milon CEO jean-philippe.milon@quantum-genomics.comBenoît Gueugnon CFO benoit.gueugnon@quantum-genomics.com So Bang (Europe)   Nathalie Boumendil Financial Communications +33 (0)6 85 82 41 95 | nathalie@so-bang.frSamuel Beaupain Media Relations and Scientific Communications +33 (0)6 88 48 48 02 | samuel@so-bang.fr LifeSci (USA)  Dan Ferry Financial Communications +1 (617) 430-7576 | Daniel@lifesciadvisors.com Mike Tattory Media Relations and Scientific Communications +1 (609) 802-6265 | mtattory@lifescicomms.com